marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-14-2024
Lineage Cell Therapeutics Balance Sheet 2011-2024 | LCTX
Annual Balance Sheet Lineage Cell Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-34.5 M | -10.4 M | -54.9 M | -28.8 M | -4.33 M | -21.3 M | -36.7 M | -20 M | -41.6 M | -29 M | -5.5 M | -4.35 M | -22.2 M |
Long Term Debt |
91 K | 84 K | 30 K | - | - | - | 18 K | 1.15 M | 544 K | - | - | - | - |
Long Term Debt Current |
830 K | 916 K | 801 K | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 5.05 M | 7.74 M | 2.6 M | 2.1 M | 3.21 M | 5.75 M | 5.05 M | 8.51 M | 1.06 M | 1.22 M |
Total Current Liabilities |
18 M | 19 M | 47.1 M | 7.77 M | 6.49 M | 6.81 M | 6.88 M | 8.85 M | 12.5 M | 7.13 M | 6.96 M | 4.39 M | 3.15 M |
Total Liabilities |
39 M | 51.7 M | 83.6 M | 12.8 M | 14.2 M | 9.41 M | 8.98 M | 12.1 M | 18.2 M | 12.2 M | 15.5 M | 5.45 M | 4.37 M |
Deferred Revenue |
10.8 M | 9.42 M | 18.1 M | 193 K | 45 K | 42 K | 797 K | 572 K | 2.95 M | 208 K | 235 K | 401 K | 466 K |
Retained Earnings |
-385 M | -363 M | -337 M | -294 M | -273 M | -262 M | -216 M | -196 M | -229 M | -182 M | -146 M | -102 M | -80.5 M |
Total Assets |
101 M | 124 M | 175 M | 108 M | 125 M | 102 M | 173 M | 143 M | 94.7 M | 74.9 M | 57.7 M | 29.7 M | 45.8 M |
Cash and Cash Equivalents |
35.4 M | 11.4 M | 55.7 M | 32.6 M | 9.5 M | 23.6 M | 36.8 M | 22.1 M | 42.2 M | 29.5 M | 5.5 M | 4.35 M | 22.2 M |
Book Value |
62 M | 71.9 M | 90.9 M | 95.1 M | 111 M | 92.2 M | 164 M | 131 M | 76.4 M | 62.7 M | 42.3 M | 24.3 M | 41.5 M |
Total Shareholders Equity |
63.4 M | 73.3 M | 92.2 M | 96.2 M | 113 M | 93.8 M | 163 M | 118 M | 26.9 M | 36.5 M | 14.8 M | 9.58 M | 28.6 M |
All numbers in USD currency
Quarterly Balance Sheet Lineage Cell Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
80 K | 68 K | 79 K | 91 K | 97 K | 113 K | 133 K | 84 K | 16 K | 19 K | 26 K | 30 K | 12 K | 16 K | 26 K | 26 K | 26 K | 26 K | 26 K | 77 K | 77 K | 77 K | 77 K | 104 K | 104 K | 104 K | 104 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.5 M | 18.2 M | 5.59 M | 5.47 M | 3.99 M | 5.11 M | 5.05 M | 5.05 M | 5.05 M | 8.51 M | 8.51 M | 8.51 M | 8.51 M | 1.06 M | 1.06 M | 1.06 M | 1.06 M | 1.22 M | 1.22 M | 1.22 M | 1.22 M |
Total Liabilities |
31.8 M | 35.9 M | 37.5 M | 39 M | 39.5 M | 40.4 M | 44.2 M | 51.7 M | 53.6 M | 54.4 M | 59.3 M | 83.6 M | 11.6 M | 11.2 M | 11.4 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 9.41 M | 9.41 M | 9.41 M | 9.41 M | 8.98 M | 8.98 M | 8.98 M | 8.98 M | 12.1 M | 12.1 M | 12.1 M | 12.1 M | 18.2 M | 18.2 M | 18.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
8.25 M | 9.14 M | 10.1 M | 10.8 M | 9.92 M | 10.4 M | 11 M | 9.42 M | 12.4 M | 15.8 M | 14.9 M | 18.1 M | 975 K | 613 K | 101 K | 193 K | 193 K | 297 K | 193 K | 45 K | 182 K | 45 K | 43 K | 42 K | 42 K | 103 K | 202 K | 309 K | 513 K | 309 K | 309 K | 572 K | 537 K | 572 K | 572 K | 439 K | 439 K | 439 K | 439 K | 208 K | 208 K | 208 K | 208 K | 235 K | 235 K | 235 K | 235 K | 401 K | 401 K | 401 K | 401 K | 204 K | 204 K | 204 K | 204 K |
Retained Earnings |
-400 M | -397 M | -391 M | -385 M | -380 M | -373 M | -368 M | -363 M | -357 M | -351 M | -344 M | -337 M | -308 M | -300 M | -295 M | -294 M | -294 M | -294 M | -294 M | -273 M | -273 M | -273 M | -273 M | -262 M | -262 M | -262 M | -262 M | -216 M | -216 M | -216 M | -216 M | -196 M | -196 M | -196 M | -196 M | -230 M | -229 M | -229 M | -229 M | -182 M | -182 M | -182 M | -182 M | -146 M | -146 M | -146 M | -146 M | -102 M | -102 M | -102 M | -102 M | -80.5 M | -80.5 M | -80.5 M | -80.5 M |
Total Assets |
96.6 M | 103 M | 108 M | 101 M | 106 M | 112 M | 113 M | 124 M | 131 M | 136 M | 145 M | 175 M | 131 M | 135 M | 128 M | 108 M | 108 M | 108 M | 108 M | 125 M | 125 M | 125 M | 125 M | 102 M | 102 M | 102 M | 102 M | 173 M | 173 M | 173 M | 173 M | 143 M | 143 M | 143 M | 143 M | 94.7 M | 94.7 M | 94.7 M | 94.7 M | 74.9 M | 74.9 M | 74.9 M | 74.9 M | 57.7 M | 57.7 M | 57.7 M | 57.7 M | 29.7 M | 29.7 M | 29.7 M | 29.7 M | 45.8 M | 45.8 M | 45.8 M | 45.8 M |
Cash and Cash Equivalents |
27.8 M | 29.6 M | 43.6 M | 35.4 M | 31.5 M | 33.9 M | 15.5 M | 11.4 M | 24.8 M | 70.9 M | 78.1 M | 55.7 M | 60.8 M | 62 M | 56.2 M | 32.6 M | 32.6 M | 32.6 M | 32.6 M | 9.5 M | 9.5 M | 9.5 M | 9.5 M | 23.6 M | 23.6 M | 23.6 M | 23.6 M | 36.8 M | 36.8 M | 36.8 M | 36.8 M | 22.1 M | 22.1 M | 22.1 M | 22.1 M | 42.2 M | 42.2 M | 42.2 M | 42.2 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M | 5.5 M | 5.5 M | 5.5 M | 5.5 M | 4.35 M | 4.35 M | 4.35 M | 4.35 M | 22.2 M | 22.2 M | 22.2 M | 22.2 M |
Book Value |
64.8 M | 66.9 M | 71 M | 62 M | 66.7 M | 71.3 M | 69 M | 71.9 M | 77.6 M | 81.5 M | 85.2 M | 90.9 M | 120 M | 124 M | 117 M | 95.1 M | 95.1 M | 95.1 M | 95.1 M | 111 M | 111 M | 111 M | 111 M | 92.2 M | 92.2 M | 92.2 M | 92.2 M | 164 M | 164 M | 164 M | 164 M | 131 M | 131 M | 131 M | 131 M | 76.4 M | 76.4 M | 76.4 M | 94.7 M | 74.9 M | 74.9 M | 74.9 M | 74.9 M | 57.7 M | 57.7 M | 57.7 M | 57.7 M | 29.7 M | 29.7 M | 29.7 M | 29.7 M | 45.8 M | 45.8 M | 45.8 M | 45.8 M |
Total Shareholders Equity |
66.2 M | 68.3 M | 72.4 M | 63.4 M | 66.7 M | 71.3 M | 69 M | 73.3 M | 77.6 M | 81.5 M | 85.2 M | 92.2 M | 120 M | 124 M | 117 M | 96.2 M | 96.2 M | 96.2 M | 96.2 M | 113 M | 113 M | 113 M | 113 M | 92.2 M | 93.8 M | 93.8 M | 93.8 M | 163 M | 163 M | 163 M | 163 M | 118 M | 118 M | 118 M | 118 M | 25.8 M | 26.9 M | 26.9 M | 26.9 M | 36.5 M | 36.5 M | 36.5 M | 36.5 M | 14.8 M | 14.8 M | 14.8 M | 14.8 M | 9.58 M | 9.58 M | 9.58 M | 9.58 M | 28.6 M | 28.6 M | 28.6 M | 28.6 M |
All numbers in USD currency